Skip to content

Study · Systematic review · 2023

2 results

The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus-A Systematic Review.

Bica IC, Pietroșel VA, Salmen T, Diaconu CT, Fierbinteanu Braticevici C, Stoica RA, Suceveanu AI, Pantea Stoian A

International journal of molecular sciences13 Apr 2023Cited by 17 (Europe PMC)

PMID37108347 (opens in a new tab)PMCIDPMC10138454 (opens in a new tab)DOI10.3390/ijms24087184 (opens in a new tab)PepBankPUB-37108347
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

As the pathophysiologic mechanisms of type 2 diabetes mellitus (T2DM) are discovered, there is a switch from glucocentric to a more comprehensive, patient-centered management. The holistic approach considers the interlink between T2DM and its complications, finding the best therapies for minimizing the cardiovascular (CV) or renal risk and benefitting from the treatment's pleiotropic effects. Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) fit best in the holistic approach because of their effects in reducing the risk of CV events and obtaining better metabolic control. Additionally, research on the SGLT-2i and GLP-1 RA modification of gut microbiota is accumulating. The microbiota plays a significant role in the relation between diet and CV disease because some intestinal bacteria lead to an increase in short-chain fatty acids (SCFA) and consequent positive effects. Thus, our review aims to describe the relation between antidiabetic non-insulin therapy (SGLT-2i and GLP-1 RA) with CV-proven benefits and the gut microbiota in patients with T2DM. We identified five randomized clinical trials including dapagliflozin, empagliflozin, liraglutide, and loxenatide, with different results. There were differences between empagliflozin and metformin regarding the effects on microbiota despite similar glucose control in both study groups. One study demonstrated that liraglutide induced gut microbiota alterations in patients with T2DM treated initially with metformin, but another failed to detect any differences when the same molecule was compared with sitagliptin. The established CV and renal protection that the SGLT-2i and GLP-1 RA exert could be partly due to their action on gut microbiota. The individual and cumulative effects of antidiabetic drugs on gut microbiota need further research.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewMechanism

    In patients with type 2 diabetes initially treated with metformin, one included study found that liraglutide induced gut microbiota alterations.

    In plain wordsIn people with type 2 diabetes on metformin, one study found liraglutide changed the gut bacteria.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedGut microbiota alterations
    Study

    n: not reported in source

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    One study demonstrated that liraglutide induced gut microbiota alterations in patients with T2DM treated initially with metformin, but another failed to detect any differences when the same molecule was compared with sitagliptin.
    1 context sentence
    Summary · context
    We identified five randomized clinical trials including dapagliflozin, empagliflozin, liraglutide, and loxenatide, with different results.
  2. 02HumanSystematic reviewMechanism

    In patients with type 2 diabetes, another included study found no gut microbiota differences between liraglutide and sitagliptin.

    In plain wordsIn people with type 2 diabetes, another study found no difference in gut bacteria between liraglutide and sitagliptin.

    Peptide
    Liraglutide
    Outcome
    No significant changeGut microbiota differences versus sitagliptin
    Study

    n: not reported in source

    Comparator
    Sitagliptin
    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    One study demonstrated that liraglutide induced gut microbiota alterations in patients with T2DM treated initially with metformin, but another failed to detect any differences when the same molecule was compared with sitagliptin.
    1 context sentence
    Summary · context
    We identified five randomized clinical trials including dapagliflozin, empagliflozin, liraglutide, and loxenatide, with different results.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.